# US 2016/0251341 A1 · Substituted triazole compounds as serine protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251341 A1
- Document ID: US20160251341A1
- Status: Published application
- Kind: A1
- Application number: 15/056,901
- Filed: 2016-02-29
- Published: 2016-09-01
- Earliest claimed: 2015-02-27
- Applicants: Verseon Corporation
- Inventors: Kevin Michael Short
- Web page: https://patentgrep.com/patent/US20160251341A1

## CPC

- C07D 409/14: containing three or more hetero rings
- A61K 9/0048: {Eye, e.g. artificial tears}
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 249/14: Nitrogen atoms
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.

## Claims

### Claim 1

A compound with the following structure:
or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein:
L1 and L2 are independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —C(O)—, —S—, —SO—, —SO2—, —O—, —NHSO2—, —NHC(O)—, or —NR4—;
R1 and R2 are independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl;
R4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl;
V is hydrogen or substituted or unsubstituted alkyl;
W is absent, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —C(O)R6, —C(O)OR6, —SR6, —SOR6, —SO2R6, —SO2NR6R7, —OR6, —NHSO2R6, or —NR6R7, where R6 and R7 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein R6 and R7 can be combined if both are present to form a substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
X is a bond, substituted or unsubstituted alkylene, —O—, or —NR8—;
Y is a bond, substituted or unsubstituted alkylene, —O—, or —N—, provided that when Y is —O—, W is absent; and
Z is a bond, —C(O)—, substituted or unsubstituted alkylene, —O—, or —NR9—;
wherein R8 and R9 are independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —C(O)R6, —C(O)OR6, —C(O)NR6R7, —SR6, —SOR6, —SO2R6, —SO2NR6R7, —OR6, —NHSO2R6, or —NR6R7, wherein R6 and R7 are as defined above; and
provided that either at least one of X is —O— or —NR8—, Y is —O— or —N—, or Z is —O— or —NR9—.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is a bond or substituted or unsubstituted alkylene.

### Claim 3 (depends on 2)

The compound of claim 2, wherein Z is a bond or substituted or unsubstituted alkylene.

### Claim 4 (depends on 3)

The compound of claim 3, wherein Y is —N—, and W is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, —C(O)R6, —C(O)OR6, —C(O)NR6R7′—SO2R6, or SO2NR6R7, wherein R6 and R7 are independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl, or R6 and R7 can be combined if both are present to form a substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.

### Claim 5 (depends on 4)

The compound of claim 4, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and Z is a bond.

### Claim 6 (depends on 4)

The compound of claim 4, wherein X is a bond, and Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

### Claim 7 (depends on 4)

The compound of claim 4, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and wherein Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

### Claim 8 (depends on 7)

The compound of claim 7, wherein X and Z are both branched alkylene and X and Z are covalently attached.

### Claim 9 (depends on 6, 7, 8)

The compound of any of claims 6-8, wherein Z is selected from the group consisting of substituted methylene, substituted ethylene, substituted propylene, substituted butylene, and substituted pentylene, having one or more substituent groups selected from the group consisting of —OH, —NH2, —SH, —CN, —CF3, —NO2, oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 10 (depends on 4)

The compound of claim 4, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and wherein Z is —C(O)—.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

The compound of any of claims 4-10, wherein W is hydrogen.

### Claim 12 (depends on 4, 5, 6, 7, 8, 9, 10)

The compound of any of claims 4-10, wherein W is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, —C(O)R6, —C(O)OR6, —C(O)NR6R7′—SR6, —SOR6, —SO2R6, and —SO2NR6.

### Claim 13 (depends on 12)

The compound of claim 12, wherein W is substituted alkyl, substituted heteroalkyl, substituted alkenyl, substituted heteroalkenyl, substituted cycloalkyl, or substituted heterocycloalkyl, having one or more substituent groups selected from the group consisting of —OH, —NH2, —SH, —CN, —CF3, —NO2, oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 14 (depends on 12)

The compound of claim 12, wherein W is —COR6, —C(O)OR6, —C(O)NR6R7, —SO2R6 or —SO2NR6R7, and wherein R6 and R7 are selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, or R6 and R7 combine to form a substituted or unsubstituted alkylene.

### Claim 15 (depends on 1)

The compound of claim 1, wherein W is absent, X is —NRB—, Y is a bond or substituted or unsubstituted alkylene, and Z is —NR9—.

### Claim 16 (depends on 15)

The compound of claim 15, wherein Y is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

### Claim 17 (depends on 16)

The compound of claim 16, wherein R8 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, —COR6, —C(O)OR6, —C(O)NR6R7, —SR6, —SOR6, —SO2R6, and —SO2NR6R7, and wherein R9 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, —COR6, —C(O)OR6, —C(O)NR6R7, —SR6, —SOR6, —SO2R6, and —SO2NR6R7.

### Claim 18 (depends on 3)

The compound of claim 3, wherein Y is —O—, and W is absent.

### Claim 19 (depends on 18)

The compound of claim 18, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and Z is a bond.

### Claim 20 (depends on 18)

The compound of claim 18, wherein X is a bond, and Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

### Claim 21 (depends on 18)

The compound of claim 18, wherein X is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene, and wherein Z is selected from the group consisting of substituted or unsubstituted methylene, substituted or unsubstituted ethylene, substituted or unsubstituted propylene, substituted or unsubstituted butylene, and substituted or unsubstituted pentylene.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any of claims 1-21, wherein V is hydrogen or substituted or unsubstituted methyl.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound according to any of claims 1-22, wherein L1 is —S—, —O—, —NR4—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene; R1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; and R4 is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heterocycloalkyl.

### Claim 24 (depends on 23)

The compound according to claim 23, wherein L1 is —NR4— or substituted or unsubstituted heteroalkyl, and R1 is substituted or unsubstituted alkyl or substituted or unsubstituted heteroaryl.

### Claim 25 (depends on 24)

The compound according to claim 24, wherein L1 is —NR4—, and R1 is substituted alkyl having one or more substituent groups selected from the group consisting of substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl.

### Claim 26 (depends on 25)

The compound according to claim 25, wherein R1 is substituted alkyl substituted by chloro-substituted thiophenyl.

### Claim 27 (depends on 24)

The compound according to claim 24, wherein L1 is substituted or unsubstituted heteroalkyl, and R1 is substituted or unsubstituted heteroaryl.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound according to any of claims 1-27, wherein L2 is bond, substituted or unsubstituted alkylene, —C(O)—, or —SO2—, and R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

### Claim 29 (depends on 28)

The compound according to claim 28, wherein L2 is bond, and R2 is hydrogen.

### Claim 30 (depends on 28)

The compound according to claim 28, wherein L2 is —C(O)—, and R2 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound according to any of claims 1 to 31 as set forth in Table A, Table B, or Table C.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A pharmaceutical composition comprising a compound according to any of claims 1 to 31, or a compound as set forth in Table A, Table B, or Table C, and a pharmaceutically acceptable excipient.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method for treating and/or preventing a disease or disorder in a subject, comprising administering a compound according to any of claims 1 to 31 or a pharmaceutical composition according to claim 32, to a subject in need thereof in an amount effective to treat or prevent said disease or disorder.

### Claim 34 (depends on 33)

The method according to claim 33, wherein said disease or disorder is a thrombotic disease or disorder and/or involves a blood clot thrombus or the potential formation of a blood clot thrombus.

### Claim 35 (depends on 34)

The method according to claim 34, wherein said thrombotic disease or disorder comprises acute coronary syndrome, thromboembolism, and/or thrombosis.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the thromboembolism comprises venous thromboembolism, arterial thromboembolism, and/or cardiogenic thromboembolism.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the venous thromboembolism comprises deep vein thrombosis and/or pulmonary embolism.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the deep vein thrombosis and/or pulmonary embolism occurs following a medical procedure.

### Claim 39 (depends on 34)

The method according to claim 34, wherein said thrombotic disease or disorder involves dysfunctional coagulation or disseminated intravascular coagulation.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the subject is undergoing percutaneous coronary intervention (PCI).

### Claim 41 (depends on 34)

The method according to claim 34, wherein said thrombotic disease or disorder involves a blood clot thrombus or the potential formation of a blood clot thrombus and further involves stroke and/or one or more transient ischemic attacks (TIA).

### Claim 42 (depends on 41)

The method according to claim 41, wherein said thrombotic disease or disorder involving a blood clot thrombus or the potential formation of a blood clot thrombus further involves stroke and wherein the subject has non-valvular atrial fibrillation.

### Claim 43 (depends on 34)

The method according to claim 34, wherein said thrombotic disease or disorder involves a blood clot thrombus or the potential formation of a blood clot thrombus and further involves pulmonary hypertension.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the pulmonary hypertension is caused by one or more left heart disorder and/or chronic thromboembolic disease.

### Claim 45 (depends on 43)

The method according to claim 43, wherein the pulmonary hypertension is associated with one or more lung disease, including pulmonary fibrosis (idiopathic or otherwise), and/or hypoxia.

### Claim 46 (depends on 33)

The method according to claim 33, wherein said disease or disorder comprises fibrosis, Alzheimer's Disease, multiple sclerosis, pain, cancer, inflammation, and/or Type I diabetes mellitus.

### Claim 47 (depends on 33)

The method according to claim 33, wherein the disease or disorder involves recurrent cardiac events after myocardial infarction.

### Claim 48 (depends on 36)

The method according to claim 36, wherein the venous thromboembolism is associated with formation of a thrombus within a vein associated with one or more acquired or inherited risk factors and/or embolism of peripheral veins caused by a detached thrombus.

### Claim 49 (depends on 48)

The method according to claim 48, wherein the one or more risk factors comprise a previous venous thromboembolism.

### Claim 50 (depends on 36)

The method according to claim 36, wherein the cardiogenic thromboembolism is due to formation of a thrombus in the heart associated with cardiac arrhythmia, heart valve defect, prosthetic heart valves or heart disease, and/or embolism of peripheral arteries caused by a detached thrombus.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the detached thrombus is in the brain (ischemic stroke).

### Claim 52 (depends on 51)

The method according to claim 51, wherein the detached thrombus causes a transient ischemic attack (TIA).

### Claim 53 (depends on 50)

The method according to claim 50, wherein the cardiogenic thromboembolism is due to non-valvular atrial fibrillation.

### Claim 54 (depends on 35)

The method according to claim 35, wherein the thrombosis is arterial thrombosis.

### Claim 55 (depends on 54)

The method according to claim 54, wherein the arterial thrombosis is due to one or more underlying atherosclerotic processes in the arteries.

### Claim 56 (depends on 55)

The method according to claim 55, wherein the one or more underlying atherosclerotic processes in the arteries obstruct or occlude an artery, cause myocardial ischemia (angina pectoris, acute coronary syndrome), cause myocardial infarction, obstruct or occlude a peripheral artery (ischemic peripheral artery disease), and/or obstruct or occlude the artery after a procedure on a blood vessel (reocclusion or restenosis after transluminal coronary angioplasty, reocclusion or restenosis after percutaneous transluminal angioplasty of peripheral arteries).

### Claim 57 (depends on 33)

The method according to claim 33, wherein the treatment or prevention comprises an adjunct therapy.

### Claim 58 (depends on 57)

The method according to claim 57, wherein the subject has myocardial infarction, and the adjunct therapy is in conjunction with thrombolytic therapy.

### Claim 59 (depends on 57)

The method according to claim 57, wherein the subject has unstable angina pectoris, thrombosis, and/or heparin-induced thrombocytopenia, and the adjunct therapy is in combination with antiplatelet therapy.

### Claim 60 (depends on 57)

The method according to claim 57, wherein the subject has non-valvular atrial fibrillation, and the adjunct therapy is in conjunction with one or more other therapies.

### Claim 61 (depends on 33)

The method according to claim 33, wherein said disease or disorder is a kallikrein-related disorder.

### Claim 62 (depends on 61)

The method according to claim 61, wherein said kallikrein-related disorder is a thrombotic disease, a fibrinolytic disease, a fibrotic disorder, a type of cancer, an inflammatory condition, or a dermatological condition.

### Claim 63 (depends on 61)

The method according to claim 61, wherein said kallikrein-related disorder is an ophthalmic disease.

### Claim 64 (depends on 63)

The method according to claim 63, wherein said compound or pharmaceutical composition is administered in the form of an ophthalmic composition applied topically to the eye.

### Claim 65 (depends on 64)

The method according to claim 64, wherein the ophthalmic composition is in the form of eye drops.

### Claim 66 (depends on 63)

The method according to claim 63, wherein said compound or pharmaceutical composition is administered in the form of an ophthalmic composition via intravitreal injection.

### Claim 67 (depends on 63)

The method according to claim 63, wherein said ophthalmic disease is diabetic macular edema, hereditary angioedema, age-related macular degeneration, or diabetic retinopathy.

### Claim 68 (depends on 62)

The method according to claim 62, wherein said type of cancer is selected from the group consisting of cervical-, testicular-, or non-small-cell lung adenocarcinoma, limited small cell lung cancer, glioma, malignant breast cancer, micrometastasis (e.g. micrometastasis of blood or liver), lung metastasis, and prostatic cancer.

### Claim 69 (depends on 62)

The method according to claim 62, wherein said inflammatory condition is sepsis, inflammatory bowel disease, inflammatory arthritis, systemic inflammatory response syndrome, or rheumatoid arthritis.

### Claim 70 (depends on 62)

The method according to claim 62, wherein said dermatological condition is atopic dermatitis, psoriasis, or Netherton Syndrome.

### Claim 71 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method according to any of claims 33-70, wherein said compound acts by inhibiting thrombin and/or kallikrein.

### Claim 72 (depends on 71)

The method according to claim 71, wherein said compound acts by inhibiting tissue kallikrein and/or plasma kallikrein.

### Claim 73 (depends on 33)

The method according to claim 33, wherein the amount of compound administered is a therapeutically effective dose sufficient to achieve an initial concentration of the compound or its active metabolite(s) in plasma within a range of 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM, 100-200 μM, 200-500 μM, or 500-1000 μM, or greater.

### Claim 74 (depends on 73)

The method according to claim 73, wherein greater than 50% of the initial compound concentration persists in the plasma for 1 hour, 3 hours, or longer, after intravenous injection.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

A compound according to any of claims 1 to 31 or a pharmaceutical composition according to claim 32 for use in a method according to any of claims 33-74.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound according to any of claims 1-31, wherein the compound has inhibitory activity against thrombin and/or plasma kallikrein within a range of 1-10 nM, 10-100 nM, 0.1-1 μM, 1-10 μM, 10-100 μM, 100-200 μM, 200-500 μM, or 500-1000 μM, or greater.
